1. Acknowledgement to Referees

   Acknowledgement to Referees 07 November 2023 Pages: 803 - 806

2. EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

   • Xiuning Le
   • Eric Nadler
   • John Victor Heymach

   Commentary Open access 04 October 2023 Pages: 807 - 817

   

3. Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology

   • Alessandro Ottaiano
   • Francesco Sabbatino
   • Guglielmo Nasti

   Commentary 21 October 2023 Pages: 819 - 820

4. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer

   • Lauren C. Bylsma
   • Xerxes Pundole
   • Anne-Marie C. Dingemans

   Systematic Review Open access 06 November 2023 Pages: 821 - 835

   

5. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer

   • Vivian Peirce
   • Michael Paskow
   • Sukhvinder Johal

   Review Article Open access 26 September 2023 Pages: 837 - 852

   

6. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

   • Albiruni R. Abdul Razak
   • Hung-Ming Wang
   • Jean-Pierre Delord

   Original Research Article Open access 25 October 2023 Pages: 853 - 868

   

7. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China

   • Minmin Zhao
   • Shanhu Qiu
   • Yang Shen

   Original Research Article Open access 17 October 2023 Pages: 869 - 883

   

8. Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience

   • Danilo De Novellis
   • Raffaele Fontana
   • Carmine Selleri

   Original Research Article Open access 25 September 2023 Pages: 885 - 892

9. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

   • Alexandr Poprach
   • Igor Kiss
   • Tomas Buchler

   Original Research Article 13 November 2023 Pages: 893 - 903

   

10. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

    • Estelle Dhamelincourt
    • Renaud Descourt
    • Florian Guisier

    Original Research Article 15 November 2023 Pages: 905 - 914

    

11. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

    • Kenji Morimoto
    • Tadaaki Yamada
    • Koichi Takayama

    Original Research Article 30 October 2023 Pages: 915 - 925

    

12. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers

    • Marine Marchal
    • Vincent Leroy
    • Alexis B. Cortot

    Original Research Article Open access 03 November 2023 Pages: 927 - 939

    

13. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma

    • Ning Wang
    • Zhenxian Mo
    • Wenyu Li

    Original Research Article 19 October 2023 Pages: 941 - 952

    

14. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators

    • Francesco Volta
    • Silvia La Monica
    • Roberta Alfieri

    Original Research Article Open access 19 October 2023 Pages: 953 - 964

    

15. Durvalumab: A Review in Advanced Biliary Tract Cancer

    • Simon Fung
    • Yahiya Y. Syed

    Adis Drug Evaluation Open access 09 November 2023 Pages: 965 - 972

    

16. Ivosidenib: A Review in Advanced Cholangiocarcinoma

    • James E. Frampton

    Adis Drug Evaluation 19 October 2023 Pages: 973 - 980

    

17. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma

    • Connie Kang

    Adis Drug Evaluation 03 October 2023 Pages: 981 - 989

    

18. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

    • Xiuning Le
    • Eric Nadler
    • John Victor Heymach

    Correction Open access 27 October 2023 Pages: 991 - 991